BRPI0514729A - tratamento da infecção por hiv por modulação de célula t - Google Patents

tratamento da infecção por hiv por modulação de célula t

Info

Publication number
BRPI0514729A
BRPI0514729A BRPI0514729-8A BRPI0514729A BRPI0514729A BR PI0514729 A BRPI0514729 A BR PI0514729A BR PI0514729 A BRPI0514729 A BR PI0514729A BR PI0514729 A BRPI0514729 A BR PI0514729A
Authority
BR
Brazil
Prior art keywords
cell
hiv infection
treatment
hiv
cell modulation
Prior art date
Application number
BRPI0514729-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Werner Krause
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0514729A publication Critical patent/BRPI0514729A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0514729-8A 2004-08-30 2005-07-28 tratamento da infecção por hiv por modulação de célula t BRPI0514729A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60517304P 2004-08-30 2004-08-30
PCT/EP2005/008325 WO2006024354A1 (en) 2004-08-30 2005-07-28 Treatment of hiv infection by t-cell modulation

Publications (1)

Publication Number Publication Date
BRPI0514729A true BRPI0514729A (pt) 2008-06-24

Family

ID=35079284

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514729-8A BRPI0514729A (pt) 2004-08-30 2005-07-28 tratamento da infecção por hiv por modulação de célula t

Country Status (14)

Country Link
US (1) US20060057620A1 (https=)
EP (1) EP1784217A1 (https=)
JP (1) JP2008511559A (https=)
KR (1) KR20070050934A (https=)
AU (1) AU2005279460A1 (https=)
BR (1) BRPI0514729A (https=)
CA (1) CA2570735A1 (https=)
IL (1) IL179856A (https=)
MX (1) MX2007002188A (https=)
NO (1) NO20071700L (https=)
RU (1) RU2393872C2 (https=)
TW (1) TW200626172A (https=)
WO (1) WO2006024354A1 (https=)
ZA (1) ZA200702654B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008829A1 (en) * 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor

Also Published As

Publication number Publication date
KR20070050934A (ko) 2007-05-16
US20060057620A1 (en) 2006-03-16
WO2006024354A1 (en) 2006-03-09
ZA200702654B (en) 2008-08-27
CA2570735A1 (en) 2006-03-09
AU2005279460A1 (en) 2006-03-09
NO20071700L (no) 2007-05-29
IL179856A0 (en) 2007-05-15
EP1784217A1 (en) 2007-05-16
TW200626172A (en) 2006-08-01
JP2008511559A (ja) 2008-04-17
RU2393872C2 (ru) 2010-07-10
IL179856A (en) 2010-11-30
MX2007002188A (es) 2007-10-16
RU2007111566A (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
BRPI0617412B8 (pt) anticorpo antiglipicano-3, agente anticâncer compreendendo o mesmo, bem como seu uso e seu processo de produção
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
TW200734329A (en) Thiazole inhibitors targeting resistant kinase mutations
EP2583677A3 (en) Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
PH12014502847A1 (en) Combination treatment (eg with abt-072-333) of daas for use in treating hcv
NO20072733L (no) Doseformer
EA201991174A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
BR112013007423A2 (pt) terapia combinada no que diz respeito ao tratamento da infecção por hcv
MA32018B1 (fr) Vaccin
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
TNSN08144A1 (en) Kit for parenteral administration of medicaments
NO20065971L (no) Behandling av T-cellelymfoma ved a anvende 10-propargyl-10deazaaminopterin
BRPI0514729A (pt) tratamento da infecção por hiv por modulação de célula t
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
WO2008121461A3 (en) Vaccine for activating helper function of cd8+ tcells
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
BR112023024210A2 (pt) Comprimido efervescente orodispersível contendo budesonida para uso no tratamento de esofagite eosinofílica
MD20060037A (ro) Metodă de tratament al hepatitei virale acute C
BR112022021731A2 (pt) Conjugados de fármaco e anticorpo de ccr7 para tratar câncer
RU2008129232A (ru) Способ лечения туберкулеза легких у больных вич-инфекцией
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
BR112021018219A2 (pt) Método de tratamento de endocardite infecciosa
Maladkar et al. Essential Immunonutrients in COVID-19: An Evidence-Based Review.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE.